Econazole

Quick links to important sections

Econazole

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Econazole

Property Description
Active Ingredient Econazole nitrate
Form Topical cream, powder, solution, ovule
Pharmacological Class Azole antifungal agent (Antimycotic)
General Purpose Combats and eliminates fungal infections
Origin Synthetic compound (Imidazole derivative)

What Type of Medicine is Econazole? (Identity and Classification)

Econazole is a synthetic medicinal entity chemically classified as an imidazole derivative, which serves as the foundation for its active compound, Econazole nitrate. It is formally categorized within the high-level Azole antifungal agent pharmacological class, also known as an antimycotic. The drug is chemically synthesized and is typically prepared as a single-ingredient compound. Pharmacological studies have consistently supported Econazole's classification as a broad-spectrum agent for superficial mycoses, meaning it is a clinically recognized option for dealing with common fungal issues.


Econazole Composition and Therapeutic Forms (Composition and Type)

The core active substance is Econazole nitrate, which is formulated into various preparations designed for localized use. Unlike many systemic medications, Econazole is distinguished by its array of forms tailored exclusively for topical administration and vaginal administration routes, avoiding systemic delivery for superficial conditions. Its most common dosage form(s) include a smooth topical cream, which employs an emulsified lipid/water base, alongside a light topical powder, solution, and lotion. For internal localized application, specialized preparations like the vaginal ovule and suppository are utilized, featuring bases suitable for effective delivery of the active ingredient at the site of infection.


General Purpose of Econazole (High-Level Benefit)

The general purpose of Econazole is to combat and eliminate infections caused by various susceptible fungi and yeasts. It achieves this by disrupting the essential building blocks of the fungal cell structure, leading to a functional breakdown in the organism's ability to thrive. This targeted interference results in a dual therapeutic action: it exerts both a fungistatic action (stopping the fungal growth and spread) and a fungicidal action (actively killing the infectious organism). Imidazole antifungals are well-established for their effects against dermatophytes and yeasts. This overall benefit is focused on clearing the fungal proliferation and providing resolution to the underlying cause of the superficial infection.

Regulatory References

  1. Econazole Nitrate Cream - DailyMed (NIH)

What side effects are possible with Econazole?

Econazole nitrate, a topical antifungal agent, has a safety profile established through clinical trials and post-marketing surveillance, with adverse reactions organized by official frequency classifications and System Organ Class (SOC) groupings.


Localized and General Adverse Reactions

The majority of documented effects involve the Skin and Subcutaneous Tissue Disorders and the General Disorders and Administration Site Conditions. These are typically localized events at the application site.

The Common reactions (occurring in 1/100 to 1/10 patients), consistently listed in regulatory documents, include application site discomfort such as pruritus (itching), skin burning sensation, and erythema (redness).

Reactions whose frequency cannot be reliably estimated (Not Known) often arise from post-marketing reports and include more severe, systemic manifestations. These are classified under Immune System Disorders and include events like Hypersensitivity, Angioedema, and generalized Urticaria (hives).


Safety Considerations and Restrictions

Official labeling defines specific safety constraints related to patient groups and potential high-level drug interactions.

  • Hypersensitivity: The medicine is contraindicated in individuals with a known allergy to any of its components. The occurrence of Hypersensitivity and Angioedema is documented.
  • Pregnancy and Lactation: Use during the first trimester of pregnancy is restricted to when a physician judges it to be essential. During the second and third trimesters, use is advised only if clearly needed. Caution is advised during lactation as excretion into human milk is not known.
  • Drug Interactions: Due to the possibility of limited systemic absorption, concomitant administration with the oral anticoagulant warfarin has been documented to result in the enhancement of anticoagulant effect.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information indicates that overdosage of topical econazole nitrate in humans has not been reported to date. Systemic absorption of the topical formulation is extremely low, meaning overdose resulting from excessive use on the skin is not a documented clinical risk scenario.


The primary focus for overdose is on accidental ingestion (swallowing the product). Regulatory documents describe the potential clinical manifestations of accidental ingestion as being limited to the gastrointestinal system. These documented effects include nausea, vomiting, and diarrhea.

Emergency Action Required

Regulators mandate specific actions in case of accidental exposure:

  • Accidental Ingestion: In the event of swallowing the product, especially a large amount, seek immediate medical attention. You must contact a Poison Control Center or the emergency room at once.
  • Accidental Ocular Exposure: If the cream is accidentally introduced into the eyes, the area should be thoroughly washed with clean water or saline. Medical attention should be sought if symptoms, such as irritation, persist after cleansing.

Treatment described in official documents for accidental ingestion is symptomatic and consists of appropriate supportive care. The official labeling confirms that no specific antidote is known for econazole.

Therapeutic Uses of Econazole

What Econazole Treats: Main Uses and Benefits

Econazole is commonly used to address symptomatic discomfort caused by various fungal skin and mucosal infections. It is used in situations involving conditions characterized by episodic or fluctuating manifestations, such as athlete's foot, jock itch, and ringworm. Its main benefit lies in providing supportive relief and symptom management across several domains, which contributes to maintaining a sense of stability during symptomatic periods.


Targeting Itching, Irritation, and Inflammatory Symptoms

Econazole is applied across domains where additional symptomatic support is needed, helping to address symptom clusters that may become intense or disruptive. This includes symptoms related to inflammatory or irritative states such as persistent itching (pruritus), skin irritation, and noticeable redness (erythema).

“It is relevant when supportive symptom management is appropriate, and may assist with maintaining functional stability.”

Econazole offers supportive relief that helps ease the overall symptom burden, contributing to improved day-to-day comfort during periods of heightened symptoms. It is used in clinical settings that involve acute or unstable symptom patterns, assisting patients during episodes where symptoms lead to temporary functional strain or discomfort.

Quick Fact: Supports Relief from Itching


Addressing Discomfort Associated with Specific Condition Categories

This use is relevant for conditions characterized by periods of heightened symptoms, which may include acute or recurrent episodes. By offering symptomatic relief, Econazole supports the patient during difficult episodes and helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Official Eligibility Profile for Econazole

The eligibility for using Econazole is determined by regulatory bodies based on absolute contraindications and conditional limitations for specific populations.


Absolute Contraindication

Classification Population
Must Not Use Individuals with a known hypersensitivity or allergy to Econazole nitrate or any other ingredient in the specific formulation (cream, foam, or ovule).

Conditional and Restricted Use

Use of Econazole is restricted or requires caution in the following groups:

  • Pregnancy: Use is conditional. During the first trimester, use is generally discouraged unless a physician considers it essential to the patient’s welfare. Use in later trimesters is only recommended if clearly needed.
  • Lactation: Caution must be exercised when administered to a nursing mother. The official recommendation is often to decide whether to discontinue breastfeeding or discontinue therapy.
  • Pediatrics (Foam): The topical foam formulation is generally limited to patients 12 years of age and older, as safety and efficacy have not been established in younger children.
  • Geriatric Patients: The label advises caution in dose selection for individuals aged 65 and over due to insufficient clinical data in this age group, though use is not prohibited.

What should I know about interactions with other medicines?

The officially documented interaction profile for Econazole is defined by constraints related to co-administered medicines and physical product compatibility.

Interaction with Oral Anticoagulants

The most significant drug-drug interaction involves Oral Anticoagulants, specifically medicines like Warfarin and Acenocoumarol. Official regulatory information states that co-administration of Econazole with these anticoagulants can lead to the enhancement of the anticoagulant effect. This is a documented outcome requiring that patients undergo monitoring of International Normalized Ratio (INR) or prothrombin time. The risk of increased anticoagulant exposure is noted to be heightened when the Econazole product is applied to a large body surface area, under occlusion, or to the genital area. The official regulatory text attributes this interaction to the fact that Econazole is a known inhibitor of Cytochrome P450 3A4 (CYP3A4), the enzyme responsible for metabolizing these co-administered medicines.

Physical Compatibility Restriction

Econazole also has a critical non-medicinal physical restriction. Contact between the product and latex barrier contraceptives (such as condoms or diaphragms) must be avoided. The constituents within the Econazole preparation may damage the latex material, which could compromise the physical integrity of the barrier device. No drug combinations are formally classified as contraindicated. Furthermore, no interactions with food, alcohol, or herbal supplements are explicitly cited in the official regulatory documentation.

Mechanism of Action

Econazole's Dual Mechanism: Fungal Cell Target and Pathway Inhibition

Econazole's primary action involves enzyme inhibition within the fungal cell's metabolic machinery. It targets and blocks the lanosterol 14-alpha-demethylase (CYP51) enzyme, leading to a critical failure in the ergosterol biosynthesis pathway. This mechanistic domain results in the depletion of the necessary cell membrane component and the accumulation of toxic molecular byproducts, contributing to the fungicidal action.

Direct Membrane Disruption and Physiological Consequence

Beyond blocking an enzyme, Econazole physically interacts with the fungal cell membrane itself, which constitutes a distinct mechanistic domain. This direct interference rapidly compromises the structural integrity and permeability of the cell barrier. The immediate physiological consequence is the leakage of essential internal components, which compromises cellular function and results in cellular dysfunction.

Modulation of Local Host Inflammatory Signaling

A secondary mechanistic domain involves the drug's effect on the surrounding host tissue. Econazole modulates the synthesis of local eicosanoid inflammatory mediators (such as prostaglandins), thereby dampening the host's heightened inflammatory response. This action modulates host biological signaling by limiting excessive mediator release.

Dosage and Administration Information

Econazole is an antifungal medication indicated for topical application to treat certain fungal and yeast infections of the skin, such as athlete's foot, jock itch, ringworm, and cutaneous candidiasis. This medication is for external use only and is not for oral, ophthalmic, or intravaginal use.

General Application Guidelines

  1. Preparation: Wash your hands thoroughly before and after application. Clean the infected area with soap and water and ensure the skin is completely dry before applying the medication.
  2. Application: Apply a sufficient amount of the cream or foam to gently cover the affected skin area and the immediate surrounding skin. Rub the product in until most of it disappears. Use only as directed by your healthcare provider.
  3. Frequency and Duration: The dosing frequency and total duration of treatment vary based on the type of infection:
Infection Type Application Frequency Typical Duration
Cutaneous Candidiasis Twice daily (morning and evening) 2 weeks
Tinea Cruris (Jock Itch) Once daily 2 weeks
Tinea Corporis (Ringworm) Once daily 2 weeks
Tinea Pedis (Athlete's Foot) Once daily 4 weeks
  • Do not cover the treated area with an airtight or occlusive dressing unless explicitly directed by your doctor, as this may increase the amount of medication absorbed through the skin.

Important Considerations

  • Full Course: Continue to use econazole for the entire prescribed length of time, even if symptoms begin to improve quickly. Stopping treatment early may increase the risk of the infection returning or becoming resistant to medication.
  • Missed Dose: If a dose is missed, apply it as soon as you remember. If it is almost time for the next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not apply a double amount to make up for a missed dose.
  • Flammability (Foam): If using the topical foam, be aware that the contents are flammable. Avoid heat, open flame, and smoking during and immediately following the application.
  • Interactions: If you are taking the anticoagulant medication warfarin, inform your healthcare provider. Concomitant use with econazole may enhance the anticoagulant effect, and monitoring of the International Normalized Ratio (INR) may be indicated.

Recent Clinical Evidence

Econazole nitrate is a long-established, broad-spectrum imidazole antifungal medication used topically to treat various common skin infections caused by fungi and yeasts. Clinical trials have consistently demonstrated its efficacy against conditions such as tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), cutaneous candidiasis (skin yeast infections), and tinea versicolor.


Clinical Efficacy and Formulations

Recent clinical studies and data reviews confirm the high rates of mycological cure (elimination of the fungus) associated with econazole cream, often showing cure rates above 85% in cases of tinea pedis and other dermatophytoses following a standard course of treatment, typically lasting two to four weeks depending on the infection type. While the 1% cream remains a widely used and effective formulation, a 1% topical foam has been developed for the treatment of interdigital tinea pedis (athlete's foot between the toes) in patients aged 12 years and older. Comparative trials for this newer foam formulation have shown significantly higher complete and mycological cure rates compared to the inactive vehicle alone.


Safety Profile and Emerging Research

Econazole is generally well-tolerated, with its safety profile primarily limited to mild, temporary local reactions at the application site, such as slight burning or irritation. Systemic absorption following topical use is minimal, which contributes to a low risk of systemic side effects. Of note, novel research is exploring the antifungal agent's potential applications beyond its traditional indications. Preclinical studies suggest econazole may possess a selective cell-death inducing effect on certain tumor cells related to Neurofibromatosis type 1 (NF1), a genetic disorder. This emerging area of investigation suggests a possibility for new, non-traditional therapeutic uses for econazole in the future, though this research remains in early stages.

Frequently Asked Questions (FAQ)

Common questions about Econazole (FAQ)


Q: How long does it usually take to see results from using Econazole cream?

Clinical studies have noted that patients report early symptomatic relief after beginning treatment. Initial clinical improvement has been observed within the first couple of weeks in trials, with the timeframe varying based on the specific infection being treated.

Q: Is it safe to use Econazole if I am pregnant or breastfeeding?

Official labeling restricts use during the first trimester of pregnancy to cases where a physician determines it is essential. Regulatory documents state that use in the second and third trimesters is considered appropriate only if clearly needed. It is not known whether the medicine is passed into human milk, and regulatory caution is advised when the medicine is administered to a nursing mother.

Q: Can Econazole affect birth control pills or other hormonal medications?

The official regulatory documents identify a risk of interaction primarily with the blood-thinning medicine warfarin and a physical compatibility issue with latex barrier contraceptives. The labeling does not explicitly cite any formal interactions with oral contraceptive pills or other hormonal medications.

Q: What research evidence supports the use of Econazole for fungal infections?

Econazole is approved for topical use based on clinical trials demonstrating its effectiveness against specific fungal infections like athlete's foot, jock itch, ringworm, cutaneous candidiasis, and tinea versicolor. This evidence supports its official regulatory indication for treating these conditions.

Q: Can Econazole be used on genital or perianal areas?

The official indications include infections like tinea cruris (jock itch) and cutaneous candidiasis, which can affect these areas. Official documents note that applying Econazole to the genital area may heighten the risk of an interaction with warfarin, and monitoring of coagulation parameters may be indicated.

Q: Is it normal to feel a mild burning sensation when I first apply Econazole?

Yes, official documentation lists a skin burning sensation, itching (pruritus), and redness (erythema) as common adverse effects reported during clinical trials. These localized reactions are typical for many topical antifungal treatments.

Q: What is the purpose of the other ingredients in the Econazole cream besides the active drug?

The cream contains inactive ingredients, often called excipients, such as mineral oil, benzoic acid, and butylated hydroxytoluene. These components create the water-miscible base needed to carry the active antifungal agent (Econazole nitrate) and allow it to be applied smoothly to the skin.

Q: Are there different strengths of Econazole cream or powder?

The most widely used and officially labeled form of the cream and topical foam is the 1% Econazole Nitrate strength. While Econazole comes in various forms like a powder and cream, the official labeling for the cream and foam usually specifies this 1% concentration.

Q: Is Econazole safe for use in children or infants?

The topical foam formulation is specifically restricted to patients 12 years of age and older. For the widely available cream, official regulatory information states that safety and effectiveness have not been established in the younger pediatric population.

Q: Is it true that Econazole can sometimes be used to treat certain bacterial infections?

Econazole is classified and approved as an antifungal agent. Its official indications are limited to infections caused by susceptible fungi and yeasts, and it is not approved for the treatment of bacterial infections.

Q: How quickly is Econazole absorbed into the bloodstream from the skin?

According to the official pharmacokinetics data, systemic absorption of Econazole nitrate following topical application to the skin is extremely low. Typically, less than 1% of the applied dose is absorbed and recovered through the urine and feces.

Q: Does Econazole have an age restriction for use?

Yes, the topical foam formulation has an age restriction, being indicated only for patients aged 12 years and older. The cream formulation does not have established safety and efficacy data for use in children.

Q: Is there evidence that Econazole is more or less effective depending on the fungal species?

Official information confirms that Econazole is active against the specific fungal strains listed in its indications, including certain dermatophytes (which cause ringworm) and the yeast Candida albicans in clinical infections, demonstrating targeted efficacy.

Q: Does Econazole interact with alcohol consumption?

Official regulatory documentation for the topical cream and foam does not explicitly cite any drug-drug interactions involving alcohol consumption.

Q: Is it possible to overdose by applying too much Econazole cream?

Because systemic absorption of the topical cream is extremely low, the potential for topical overdose is minimal. In the event of accidental ingestion or applying excessive amounts, information should be sought from a Poison Control Center or healthcare professional.

Q: Are there any long-term effects described for using Econazole for many years?

Regulatory documents establish the duration of treatment for the approved indications as typically short-term, ranging from two to four weeks. The long-term effects or consequences of using the medicine for many years are not addressed in the approved labeling.

Q: Can Econazole be used to treat pityriasis versicolor?

Yes, Econazole Nitrate Cream 1% is specifically indicated for the topical treatment of tinea versicolor (also known as pityriasis versicolor).

Q: What happens if Econazole gets into my eyes or mouth?

The product is for topical use only and is explicitly not for oral or ophthalmic use. It is necessary to avoid introducing the cream or foam into the eyes or mouth.

Q: Can I use other non-latex barrier contraceptives with Econazole?

The official labeling specifies a physical compatibility restriction, advising that contact must be avoided only with latex barrier contraceptives (such as condoms or diaphragms). No information is cited regarding the compatibility or safety of non-latex barrier materials.

Q: Is Econazole known to interact with herbal supplements or vitamins?

Official regulatory documentation explicitly states that no formal interactions with food or herbal supplements are cited for the topical Econazole nitrate cream or foam.

How should Econazole be stored and disposed of?

Storage and Disposal Conditions for Econazole

Official regulatory guidelines define specific conditions to maintain product stability and safety for Econazole. Both formulations must be kept out of the reach of children.


Storage Requirements

  • Econazole Cream: Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) and must not be frozen.
  • Econazole Foam: Store at Room Temperature and must not be refrigerated or frozen. Due to its pressurized, flammable nature, do not store the container above 120 F (49 C) or in direct sunlight.

Disposal Instructions

Expired or unused Econazole should be discarded according to instructions from a pharmacist or healthcare professional. The pressurized foam container specifically must not be punctured or incinerated.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Econazole found in:

A-Z Index: